Production of Recombinant Protein of Salsola Kali (Sal k1) Pollen Allergen in Lactococcus Lactis
-
Ziba Ghasemi
,
Abdol-Reza Varasteh
,
Malihe Moghadam
,
Farnaz Sedghi
,
Farahzad Jabbari Azad
,
Mojtaba Sankian
Abstract
The Salsola kali pollen is considered the main cause of allergic sensitization in desert and semi-desert regions. We have constructed recombinant Lactococcus lactis producing Sal k1 protein with the aim of using it as a mucosal vaccine for specific immunotherapy. The Sal k1 gene was amplified, and transferred into a PNZ 8148 plasmid. The PNZ8148-Sal k1 recombinant plasmid was transformed into competent E.coli strain MC1061 for replication, and then was isolated and cloned into competent L. lactis by electroporation. The cloning was verified by PCR and gene sequencing. The production of recombinant Sal K1 (rSal K1) protein was induced by nisin. The rSal K1 protein was purified by affinity chromatography and dialysis, and confirmed by SDS-PAGE and western blot analyses. The recombinant L. lactis was successfully constructed. Production of a 40-kDa rSal k1 protein with the L. lactis was shown by sodium dodecyl sulfate-polyacrylamid gel electrophoresis (SDS-PAGE) analysis. In addition, western blot analysis using specific mouse anti-Sal k1 polyclonal antibodies and sensitive human sera verified the 40-kD protein as rSal k1 allergen. This study demonstrated that L. lactis may be used as a promising live delivery system for recombinant Sal k1 protein without altering its immunoreactivity; however, its efficacy in the context of the immune system is suggested to be pursued in future studies.
1. Assarehzadegan MA, Sankian M, Jabbari F, Noorbakhsh R, Varasteh A. Allergy to Salsola Kali in a Salsola incanescens-rich area: role of extensive cross allergenicity. Allergol Int 2009; 58(2):261-6.
2. Barderas R, Garcia-Selles J, Salamanca G, Colas C, Barber D, Rodriguez R, et al. A pectin methylesterase as an allergenic marker for the sensitization to Russian thistle (Salsola kali) pollen. Clin Exp Allergy 2007; 37(7):1111-9.
3. Ferrer A, Larramendi CH, Huertas AJ, Pagan JA, Andreu C, Garcia-Abujeta JL, et al. Allergenic differences among pollens of three Salsola species. Int Arch Allergy Immunol 2010; 151(3):199-206.
4. Al-Dowaisan A, Fakim N, Khan MR, Arifhodzic N, Panicker R, Hanoon A, et al. Salsola pollen as a predominant cause of respiratory allergies in Kuwait. Ann Allergy Asthma Immunol 2004; 92(2):262-7.
5. Shafiee A, Yunginger JW, Gleich GJ. Isolation and characterization of Russian thistle (Salsola pestifer) pollen allergens. J Allergy Clin Immunol 1981; 67(6):472-81.
6. Carnes J, Fernandez-Caldas E, Marina A, Alonso C, Lahoz C, Colas C, et al. Immunochemical characterization of Russian thistle (Salsola kali) pollen extracts. Purification of the allergen Sal k 1. Allergy 2003; 58(11):1152-6.
7. Farrokhi S, Gheybi MK, Movahed A, Tahmasebi R, Iranpour D, Fatemi A, et al. Common aeroallergens in patients with asthma and allergic rhinitis living in southwestern part of Iran: based on skin prick test reactivity. Iran J Allergy Asthma Immunol 2015; 14(2):133-8.
8. Cano-Garrido O, Seras-Franzoso J, Garcia-Fruitos E. Lactic acid bacteria: reviewing the potential of a promising delivery live vector for biomedical purposes. Microb Cell Fact 2015; 14:137.
9. Daniel C, Repa A, Wild C, Pollak A, Pot B, Breiteneder H, et al. Modulation of allergic immune responses by mucosal application of recombinant lactic acid bacteria producing the major birch pollen allergen Bet v 1. Allergy 2006; 61(7):812-9.
10. Hanniffy S, Wiedermann U, Repa A, Mercenier A, Daniel C, Fioramonti J, et al. Potential and opportunities for use of recombinant lactic acid bacteria in human health. Adv Appl Microbiol 2004; 56:1-64.
11. Zanirati DF, Abatemarco M, Jr., Sandes SH, Nicoli JR, Nunes AC, Neumann E. Selection of lactic acid bacteria from Brazilian kefir grains for potential use as starter or probiotic cultures. Anaerobe 2015; 32:70-6.
12. Gareau MG, Sherman PM, Walker WA. Probiotics and the gut microbiota in intestinal health and disease. Nat Rev Gastroenterol Hepatol 2010; 7(9):503-14.
13. Murch SH. Toll of allergy reduced by probiotics. The Lancet. 2001;357(9262):1057-9.
14. Konings WN, Kok J, Kuipers OP, Poolman B. Lactic acid bacteria: the bugs of the new millennium. Curr Opin Microbiol 2000; 3(3):276-82.
15. Rosenfeldt V, Benfeldt E, Nielsen SD, Michaelsen KF, Jeppesen DL, Valerius NH, et al. Effect of probiotic Lactobacillus strains in children with atopic dermatitis. J Allergy Clin Immunol 2003; 111(2):389-95.
16. Shadnoush M, Hosseini RS, Khalilnezhad A, Navai L, Goudarzi H, Vaezjalali M. Effects of Probiotics on Gut Microbiota in Patients with Inflammatory Bowel Disease: A Double-blind, Placebo-controlled Clinical Trial. Korean J Gastroenterol 2015; 65(4):215-21.
17. Lin WH, Wu CR, Lee HZ, Kuo YH, Wen HS, Lin TY, et al. Induced apoptosis of Th2 lymphocytes and inhibition of airway hyperresponsiveness and inflammation by combined lactic acid bacteria treatment. Int Immunopharmacol 2013; 15(4):703-11.
18. Kawamoto S, Kaneoke M, Ohkouchi K, Amano Y, Takaoka Y, Kume K, et al. Sake lees fermented with lactic acid bacteria prevents allergic rhinitis-like symptoms and IgE-mediated basophil degranulation. Biosci Biotechnol Biochem 2011; 75(1):140-4.
19. Watanabe T, Hamada K, Tategaki A, Kishida H, Tanaka H, Kitano M, et al. Oral administration of lactic acid bacteria isolated from traditional South Asian fermented milk 'dahi' inhibits the development of atopic dermatitis in NC/Nga mice. J Nutr Sci Vitaminol (Tokyo) 2009; 55(3):271-8.
20. Landete JM. A review of food-grade vectors in lactic acid bacteria: from the laboratory to their application. Crit Rev Biotechnol 2017; 37(3):296-308.
21. Bahey-El-Din M, Gahan CG, Griffin BT. Lactococcus lactis as a cell factory for delivery of therapeutic proteins. Curr Gene Ther 2010; 10(1):34-45.
22. Wells J. Mucosal vaccination and therapy with genetically modified lactic acid bacteria. Annu Rev Food Sci Technol 2011; 2:423-45.
23. Repa A, Grangette C, Daniel C, Hochreiter R, Hoffmann-Sommergruber K, Thalhamer J, et al. Mucosal co-application of lactic acid bacteria and allergen induces counter-regulatory immune responses in a murine model of birch pollen allergy. Vaccine 2003; 22(1):87-95.
24. Sambrook J, Russell DW. The Inoue Method for Preparation and Transformation of Competent E. coli:" Ultra Competent" Cells. CSH Protoc 2006; 2006(1).
25. Fereidouni M, Hossini RF, Azad FJ, Assarehzadegan MA, Varasteh A. Skin prick test reactivity to common aeroallergens among allergic rhinitis patients in Iran. Allergol Immunopathol (Madr) 2009; 37(2):73-9.
26. Colas C, Monzon S, Venturini M, Lezaun A. Double-blind, placebo-controlled study with a modified therapeutic vaccine of Salsola kali (Russian thistle) administered through use of a cluster schedule. J Allergy Clin Immunol 2006; 117(4):810-6.
27. Assarehzadegan MA, Sankian M, Jabbari F, Tehrani M, Varasteh A. Expression of the recombinant major allergen of Salsola kali pollen (Sal k 1) and comparison with its low-immunoglobulin E-binding mutant. Allergol Int 2010; 59(2):213-22.
28. Mas S, Boissy P, Monsalve RI, Cuesta-Herranz J, Diaz-Perales A, Fernandez J, et al. A recombinant Sal k 1 isoform as an alternative to the polymorphic allergen from Salsola kali pollen for allergy diagnosis. Int Arch Allergy Immunol 2015; 167(2):83-93.
29. Kalliomaki MA, Isolauri E. Probiotics and down-regulation of the allergic response. Immunol Allergy Clin North Am 2004; 24(4):739-52.
30. Rautava S, Kalliomaki M, Isolauri E. New therapeutic strategy for combating the increasing burden of allergic disease: Probiotics-A Nutrition, Allergy, Mucosal Immunology and Intestinal Microbiota (NAMI) Research Group report. J Allergy Clin Immunol 2005; 116(1):31-7.
31. Steidler L, Neirynck S, Huyghebaert N, Snoeck V, Vermeire A, Goddeeris B, et al. Biological containment of genetically modified Lactococcus lactis for intestinal delivery of human interleukin 10. Nat Biotechnol 2003; 21(7):785-9.
32. LeBlanc JG, Aubry C, Cortes-Perez NG, de Moreno de LeBlanc A, Vergnolle N, Langella P, et al. Mucosal targeting of therapeutic molecules using genetically modified lactic acid bacteria: an update. FEMS Microbiol Lett 2013; 344(1):1-9.
33. Chatel JM, Nouaille S, Adel-Patient K, Le Loir Y, Boe H, Gruss A, et al. Characterization of a Lactococcus lactis strain that secretes a major epitope of bovine beta-lactoglobulin and evaluation of its immunogenicity in mice. Appl Environ Microbiol 2003; 69(11):6620-7.
34. Charng YC, Lin CC, Hsu CH. Inhibition of allergen-induced airway inflammation and hyperreactivity by recombinant lactic-acid bacteria. Vaccine 2006; 24(33-34):5931-6.
35. Adel-Patient K, Ah-Leung S, Creminon C, Nouaille S, Chatel JM, Langella P, et al. Oral administration of recombinant Lactococcus lactis expressing bovine beta-lactoglobulin partially prevents mice from sensitization. Clin Exp Allergy 2005; 35(4):539-46.
36. Bermudez-Humaran LG, Kharrat P, Chatel JM, Langella P. Lactococci and lactobacilli as mucosal delivery vectors for therapeutic proteins and DNA vaccines. Microb Cell Fact 2011; (10 Suppl 1):S4.
37. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976; 72:248-54.
| Files | ||
| Issue | Vol 17, No 2 (2018) | |
| Section | Original Article(s) | |
| Keywords | ||
| Lactococcus lactis Pollen Recombinant protein Salsola kali Sal k1 | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
